Diabetics hopeful about new treatments revealed at conference
Many new therapies for chronic health condition now being offered
Data presented at the American Diabetes Association conference in
Philadelphia has many diabetics excited about the possibility of new
treatments and medications. Results from various studies of several new
diabetes medicines and insulin products were announced and demonstrated,
giving diabetics new hope in controlling their health condition.
Novo Nordisk gave presentations on the results of degludec, ultra-long-acting insulin for patients with Type 2 diabetes.
Novo Nordisk gave presentations on the results of degludec, ultra-long-acting insulin for patients with Type 2 diabetes. In a yearlong, 1,030-patient study compared degludec with Sanofi's Lantus, the world's top-selling insulin. Degludec reduced low blood sugar during the night, when it is at its most deadly, by 36 percent. Degludec also reduced severe hypoglycemia significantly, compared to Lantus. Those problems occurred less than once in a year in both groups of patients, though.
Because degludec is active in the body for more than the standard 24 hours for long-acting insulins, patients can maintain good blood sugar control even if they don't take it at the same time every day. The Food and Drug Administration has pushed back a review of the new drug until Oct. 29 in order to allow more time to review data.
Canagliflozin, part of a newer class of diabetes drugs called SGLT2 inhibitors, was presented by Johnson & Johnson's Janssen Research unit. Demonstrated in five late-stage studies on its daily Type 2 diabetes pill, they work primarily by increasing how much glucose is excreted in urine. One year-long study found it reduced long-term blood sugar levels and also helped patients lose much more weight than Merck & Co.'s blockbuster pill Januvia.
Johnson & Johnson has applied for U.S. approval of its drug on May 29.
Eli Lilly and partner Boehringer Ingelheim of Germany also released results from two mid-stage studies of their new short-acting insulin, known as LY2605541.
LY2605541 was slightly better at reducing blood sugar levels in Type 1 diabetics and about the same in Type 2 diabetics. In the eight-week Type 1 study, patients getting LY2605541 lost about 2.5 pounds on average while those on Lantus gained 1.5 pounds. Weight changes were similar, but smaller, in the Type 2 study.
LY2605541 still must go through late-stage testing before approval can be sought.
There were many several other companies presenting data on an experimental patch to deliver insulin pain-free and two devices in early development that would work like an artificial pancreas, monitoring blood sugar continuously to help control when an insulin pump releases the hormone into the patient's blood.
© 2012, Distributed by NEWS CONSORTIUM.
- - -
Pope Benedict XVI's Prayer Intentions for January 2013
General Intention: The Faith of Christians. That in this Year of Faith Christians may deepen their knowledge of the mystery of Christ and witness joyfully to the gift of faith in him.
Missionary Intention: Middle Eastern Christians. That the Christian communities of the Middle East, often discriminated against, may receive from the Holy Spirit the strength of fidelity and perseverance.
Keywords: Diabetes, new medications, degludec, Canagliflozin, insulin
Rate This Article
Leave a Comment
More Health News
- HIV resurgent among Navajo tribe as deadly cases spike
- UK to give cancer patients genetic analysis just like Angelina Jolie
- Vitamin D found beneficial in treating asthma symptoms
- Study: Depressed women in 40s, 50s suffer more than twice for stroke risk
- Some experts say it's biologically possible to clone a human
- Study: Women live longer than men as their immune systems age more slowly
- Man declared dead for 40 minutes brought back to life with revolutionary machine
- IPad2 poses risks to those with pacemakers, 14-year-old girl discovers
- New SARS-like virus can likely be spread person-to-person
- Fr. Paul Schenck: Finding Living Faith on Catechetical Sunday
- The Movie Yellow: Incest as 'Normal' and Cassavates's Slides Into the World of Woes
- The Chicago School Teachers Strike Reveals the Need For School Choice
- The Sexual Barbarians and the Dissolution of Culture
- The Happy Priest Challenges Us to Ask: Who is Jesus to Me?
- Michael Coren on Canadian Public Schools: Teachers, leave those kids alone
- We Cannot Ignore Our Consciences: Cardinal Dolan On Religious Liberty
- In the Face of Danger, Successor of Peter Travels to Lebanon as a Messenger of Peace
- Reflections on the Dignity and Vocation of Women: Who or What?